Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:10:49.027Z.
Calculation as of: 2026-10-06T14:10:49.027Z.
Quote observation: 2026-10-06T14:10:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09d62e22afa0eb1a5da77a5c6bfdaaeedfdfba09b979310b40e193a87c10cfd4
PEG RATIO
N/A
Arcturus Therapeutics Holdings Inc.
Market Cap
$392.24M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $392.24M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $387.44M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $410.20M | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $410.91M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $408.14M | N/A |
| Carlsmed, Inc. (CARL)vs › | $411.99M | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.54M | N/A |
| Canopy Growth Corporation (CGC)vs › | $375.13M | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $428.93M | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $431.90M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
